A PHASE III, MULTIZENTRUM, RANDOMISIERT, DOPPELBLINDE, PLACEBO-KONTROLLIERTE STUDIE VON ATEZOLIZUMAB (ANTI PD-L1 ANTIKÖRPER) AS ADJUVANTE THERAPIE NACH DEFINITIVER LOKALER THERAPIE BEI PATIENTEN MIT HOHEM RISIKO LOKAL FORTGESCHRITTENE PLATTENZELLEN KARZINOM VON KOPF UND HALS
This study will evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN).
